^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

KDR expression

i
Other names: VEGFR2, KDR, Vascular Endothelial Growth Factor Receptor 2, Protein-Tyrosine Kinase Receptor Flk-1, Fetal Liver Kinase 1, FLK1, CD309, CD309 Antigen
Entrez ID:
Related biomarkers:
4d
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation. (PubMed, Exp Hematol Oncol)
Our work reveals a positive feedback loop between MET and VEGF/VEGFR2, resulting in continuous downstream signal activation. Combined inhibition of MET and VEGF/VEGFR2 signaling pathway may be beneficial for reversing EGFR TKIs resistance.
Journal
|
ETS1 (ETS Proto-Oncogene 1)
|
EGFR mutation • KDR expression
|
Avastin (bevacizumab) • Xalkori (crizotinib) • gefitinib
7d
Role of β-adrenergic signaling and the NLRP3 inflammasome in chronic intermittent hypoxia-induced murine lung cancer progression. (PubMed, Respir Res)
Our study underscores the significant contribution of β-adrenergic signaling and the NLRP3 inflammasome to CIH-induced lung cancer progression. These pathways represent potential therapeutic targets for mitigating the impact of OSA on lung cancer.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CCND1 (Cyclin D1) • KDR (Kinase insert domain receptor) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • CD31 (Platelet and endothelial cell adhesion molecule 1) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
CCND1 expression • KDR expression • CD31 expression
16d
AB042. Combined anti-PD-L1 and anti-VEGFR2 therapy promotes the antitumor immune response in glioblastoma multiforme by reprogramming tumor microenvironment. (PubMed, Chin Clin Oncol)
Our results support that anti-VEGFR2 therapy can downregulate PAK4, reprogram the TME by increasing CD8+ T cells infiltration and activation, and enhance the therapeutic effect of anti-PD-L1 therapy on GBM cells.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • PAK4 (P21 (RAC1) Activated Kinase 4) • STAT3 (Signal Transducer And Activator Of Transcription 3) • GZMB (Granzyme B)
|
CD8 expression • KDR expression • PAK4 overexpression
16d
Vascular endothelial growth factor receptor 2 as a potential host target for the inhibition of enterovirus replication. (PubMed, J Virol)
Transcriptomic analysis suggests that Pazopanib's potential downstream targets involve the TSAd-Src-PI3K-Akt pathway. Our work may contribute to identifying targets for antiviral inhibitors and advancing treatments for human enterovirus infections.
Journal
|
KDR (Kinase insert domain receptor)
|
KDR expression
|
pazopanib
5ms
Elucidation of the anti-gastric cancer mechanism of Guiqi Baizhu Formula by integrative approach of chemical bioinformatics. (PubMed, Int Immunopharmacol)
In summary, this study suggested that GQBZF and its key active components (glycyrol and emodin) can suppress IGF1R/PI3K/PDK1 and VEGFR2-related signaling pathway, thereby inhibiting tumor cell proliferation and migration and inducing apoptosis. These findings provided an important strategy for developing new agents and facilitated clinical use of GQBZF against GC.
Journal
|
IGF1R (Insulin-like growth factor 1 receptor)
|
IGF1R expression • KDR expression
5ms
VEGFR2 blockade inhibits glioblastoma cell proliferation by enhancing mitochondrial biogenesis. (PubMed, J Transl Med)
VEGFR2 blockade inhibits glioblastoma progression via AKT-PGC1α-TFAM-mitochondria biogenesis signaling cascade, suggesting that VEGFR2 intervention might bring additive therapeutic values to anti-glioblastoma therapy.
Journal
|
TFAM (Transcription Factor A, Mitochondrial)
|
KDR expression
5ms
Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy. (PubMed, Chem Biol Drug Des)
In this review, we summarize the relationship between EGFR and VEGFR2 signal transduction in promoting cancer growth and how their kinase domain structures can affect the selectivity of an inhibitor as the basis for designing dual inhibitors. In addition, several recent studies on the development of dual EGFR and VEGFR2 inhibitors involving docking simulations were highlighted in this paper to provide some references such as pharmacophore features of inhibitors and key residues for further research, especially in computer-aided drug design.
Review • Journal
|
EGFR (Epidermal growth factor receptor) • KDR (Kinase insert domain receptor)
|
EGFR overexpression • KDR expression • VEGFA expression
6ms
Arene-Arene Coupled Disulfamethazines (or Sulfadiazine)-Phenanthroline-Metal(II) Complexes were Synthesized by In Situ Reactions and Inhibited the Growth and Development of Triple-Negative Breast Cancer through the Synergistic Effect of Antiangiogenesis, Anti-Inflammation, Pro-Apoptosis, and Cuproptosis. (PubMed, J Med Chem)
The molecular mechanism was confirmed that HA-Cu could downregulate the expression of key proteins in the VEGF/VEGFR2 signaling pathway and the expression of inflammatory cytokines, enhance the advantage of pro-apoptotic protein Bax, and enforce cuproptosis by weakening the expression of FDX1 and enhancing the expression of HSP70. Our research will provide a theoretical and practical reference for the development of metal-sulfamethazine and its derivatives as chemotherapy drugs for cancer treatment.
Journal
|
FDX1 (Ferredoxin 1)
|
KDR expression
6ms
Gemfibrozil-Platinum(IV) Precursors for New Enhanced-Starvation and Chemotherapy In Vitro and In Vivo. (PubMed, J Med Chem)
Following this concept, two cisplatin-like gemfibrozil-derived Pt(IV) prodrugs, GP and GPG, are synthesized. In vivo, GP showed superior antitumor activity in A2780 tumor-bearing mice with no observable tissue damage. Mechanistic studies suggested that highly selective chemotherapy could be due to the new enhanced starvation effect: blocking vasculature formation via inhibiting the CYP2C8/EETs pathway and VEGFR2, NF-κB, and COX-2 expression and cholesterol efflux and degradation acceleration via increasing ABCA1 and PPARα.
Preclinical • Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • KDR (Kinase insert domain receptor) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • ABCA1 (ATP Binding Cassette Subfamily A Member 1) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
|
BCL2 expression • KDR expression • TP53 expression • PTGS2 expression
|
cisplatin
6ms
ORF virus causes tumor-promoting inflammation in sheep and goats. (PubMed, Vet Pathol)
Finally, they found by quantitative RT-PCR the overexpression of the interleukin-6 and VEGFR2 genes in the lesioned tissues. These findings suggest that ORFV activates an inflammatory reaction characterized by CD163+ macrophages expressing EGFR and VEGFR2, which might play an oncogenic role through synergistic action with vVEGF signaling.
Journal
|
EGFR (Epidermal growth factor receptor) • KDR (Kinase insert domain receptor) • IL6 (Interleukin 6) • CD163 (CD163 Molecule)
|
EGFR expression • KDR expression
6ms
Grafted Sertoli Cells Exert Immunomodulatory Non-Immunosuppressive Effects in Preclinical Models of Infection and Cancer. (PubMed, Cells)
We found that MC-SeCs (i) provide antifungal resistance with minimum inflammatory pathology through the activation of the tolerogenic aryl hydrocarbon receptor/indoleamine 2,3-dioxygenase pathway; (ii) do not affect tumor growth in vivo; and (iii) reduce the LLC cell metastatic cancer spread associated with restricted Vegfr2 expression in primary tumors. Our results point to the fine immunoregulation of SeCs in the relative absence of overt immunosuppression in both infection and cancer conditions, providing additional support for the potential therapeutic use of SeC grafts in human patients.
Preclinical • Journal • IO biomarker • Immunomodulating
|
KDR (Kinase insert domain receptor)
|
KDR expression
6ms
Camptothecin enhances the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma. (PubMed, Sci Rep)
There was no obvious difference in body weight and liver and kidney functions between the four groups of mice. In conclusion, CPT improves the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma.
Journal • PD(L)-1 Biomarker • IO biomarker
|
KDR (Kinase insert domain receptor) • SQSTM1 (Sequestosome 1)
|
KDR expression
|
AiTan (rivoceranib)
7ms
Zeaxanthin impairs angiogenesis and tumor growth of glioblastoma: An in vitro and in vivo study. (PubMed, Arch Biochem Biophys)
Zea impairs angiogenesis and tumor growth of GBM both in vitro and in vivo. It can be declared that Zea is a potential valuable anticancer candidate for the future treatment strategy of GBM.
Preclinical • Journal • PARP Biomarker
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3)
|
KDR expression
7ms
Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma. (PubMed, Bioorg Chem)
Encouraged by its efficacy, it was further investigated for its antitumor activity and mechanism of action, using sorafenib as a reference standard...It also downregulated Notch1 protein expression and decreased TGF-β1 production. Molecular docking simulations suggest that 8e binds as a promising type II kinase inhibitor in the target kinases interacting with the key regions in their kinase domain.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • NOTCH1 (Notch 1) • KDR (Kinase insert domain receptor) • TGFB1 (Transforming Growth Factor Beta 1)
|
BRAF V600E • BRAF V600 • BRAF wild-type • FGFR1 expression • KDR expression • NOTCH1 expression
|
sorafenib
7ms
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy. (PubMed, Int J Cancer)
Medical records of patients with aGEC enrolled in the randomized phase II AIO-STO-0417 trial after treatment failure to first-line FOLFOX plus nivolumab and ipilimumab were retrospectively analyzed...Patients with CPS ≥1 in the RAM group showed better tumor control (ORR 25% vs 10%) and improved survival (total OS 11.5 vs 8.0 months; second-line OS 6.5 vs 3.9 months; PFS 4.5 vs 1.6 months) compared to the control. Prior exposure to first-line FOLFOX plus dual checkpoint inhibition followed by RAM plus chemotherapy shows favorable response and survival rates especially in patients with initial response and positive PD-L1 expression and has the potential to advance the treatment paradigm in aGEC.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • KDR expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • 5-fluorouracil • Cyramza (ramucirumab) • leucovorin calcium
7ms
The inhibitory effect of apatinib on different small cell lung cancer cells and in lung cancer-bearing mice and patients. (PubMed, Clin Respir J)
Apatinib has a significant inhibitory effect on small cell lung cancer with high expression of VEGFR2 and may be a treatment for small cell lung cancer patients.
Preclinical • Journal
|
KDR (Kinase insert domain receptor)
|
KDR overexpression • KDR expression
|
AiTan (rivoceranib)
7ms
Transmembrane modification of tumor vascular targeting peptide A7R as molecular cargo delivery tool. (PubMed, Bioorg Chem)
Utilizing Cyclo-A7R-RRR or A7R-RLLRLLR for transmembrane delivery of drug molecules could significantly improve their efficacy. Our findings broaden the potential application scenarios of A7R in targeted tumor angiogenesis.
Journal
|
KDR (Kinase insert domain receptor)
|
KDR expression
7ms
2-Desaza-annomontine (C81) impedes angiogenesis through reduced VEGFR2 expression derived from inhibition of CDC2-like kinases. (PubMed, Angiogenesis)
Surprisingly, alternative splicing of VEGFR2 was not detected. In summary, C81 and other CLK inhibitors could be promising compounds in the treatment of diseases that depend on angiogenesis and inflammation due to their impairment of both processes.
Journal
|
KDR (Kinase insert domain receptor) • CDK1 (Cyclin-dependent kinase 1)
|
KDR expression
8ms
VEGFR affects miR-3200-3p-mediated regulatory T cell senescence in tumour-derived exosomes in non-small cell lung cancer. (PubMed, Funct Integr Genomics)
In conclusion, inhibition of VEGFR2 expression in tumour cells promotes the expression of miR-3200-3p in exosomes secreted by tumour cells. miR-3200-3p enters the TME through exosomes and acts on DDB1 in Treg cells to promote senescence of Treg cells to inhibit tumour progression.
Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • GSTP1 (Glutathione S-transferase pi 1) • DDB1 (Damage Specific DNA Binding Protein 1) • MIR3200 (MicroRNA 3200) • MMP3 (Matrix metallopeptidase 3)
|
KDR expression • DDB1 overexpression
8ms
Expression of VEGFR2 Ligand Binding Domain in Pichia pink™ 4 Cells and Evaluation of Its Interactions with VEGF-A165 Receptor Binding Domain. (PubMed, Mol Biotechnol)
4-10 nM concentrations of sKDR1-3 inhibited the proliferation of HUVE cells induced by 5 nM VEGFA165-RBD. In consideration, sKDR1-3 in the nanomolar concentration range, is a promising anticancer drug to inhibit angiogenesis.
Journal
|
KDR (Kinase insert domain receptor) • VEGFA (Vascular endothelial growth factor A)
|
KDR expression
9ms
Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer. (PubMed, Transl Oncol)
Mechanistically, the expressions of VEGF, VEGFR2, PDGFR, and FGFR, as well as the phosphorylation levels of AKT, were inhibited after Bev+An treatment. In conclusion, the dual vertical targeting of VEGF and VEGFR in the CRC mice model strongly inhibited tumor growth and angiogenesis, with the suppression of the AKT signaling pathway playing a partial role.
Journal
|
FGFR (Fibroblast Growth Factor Receptor) • KDR (Kinase insert domain receptor) • ANXA5 (Annexin A5)
|
KDR expression • VEGFA expression
|
Avastin (bevacizumab) • Focus V (anlotinib)
9ms
Development of novel indazolyl-acyl hydrazones as antioxidant and anticancer agent that target VEGFR-2 in human breast cancer cells. (PubMed, Chem Biodivers)
In silico docking study revealed the favorable binding energies of -7.30 kcal/mol and -8.04 kcal/mol for compounds towards Vascular Endothelial Growth Factor Recaptor-2 (VEGFR-2), respectively. In conclusion, we have synthesized antioxidant and anticancer agents that target VEGFR-2 in breast cancer cells.
Journal
|
KDR (Kinase insert domain receptor)
|
KDR overexpression • KDR expression
9ms
Apatinib weakens proliferation, migration, invasion, and angiogenesis of thyroid cancer cells through downregulating pyruvate kinase M2. (PubMed, Sci Rep)
In summary, Apatinib has a regulatory role in TC progression, and Apatinib can block cancer cell angiogenesis by downregulating PKM2. This will provide a theoretical basis for therapy of TC.
Journal
|
KDR (Kinase insert domain receptor) • CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • PKM (Pyruvate Kinase M1/2)
|
KDR expression • CDH1 expression • VIM expression
|
AiTan (rivoceranib)
9ms
Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis. (PubMed, Laryngoscope)
Our analysis shows that RRP tissue shows elevated levels of multiple immune check point targets and VEGFR3, with varied patterns unique to each papilloma patient. Some of these immune checkpoint markers already have novel immunotherapies available or in development, providing molecular rationale to offer these systemic treatments to selected patients affected by RRP alongside VEGF inhibitors. Laryngoscope, 2024.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • KDR (Kinase insert domain receptor) • VEGFA (Vascular endothelial growth factor A) • LAG3 (Lymphocyte Activating 3) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • FLT4 (Fms-related tyrosine kinase 4) • LGALS9 (Galectin 9)
|
PD-L1 expression • PD-1 expression • CD8 expression • LAG3 expression • HAVCR2 expression • KDR expression • PD-1 elevation • TIGIT expression • PD-L2 expression
9ms
Hepatitis B Virus-Encoded MicroRNA (HBV-miR-3) Inhibits FIH-1 Expression to Promote Tumor Angiogenesis in HBV-Related Hepatocellular Carcinoma. (PubMed, J Hepatocell Carcinoma)
HBV-miR-3 was related to HCC patients' overall survival and it promoted angiogenesis by repressing FIH-1 expression. HBV-miR-3 may be a new marker for predicting prognosis and a novel target for anti-angiogenic treatment of HBV-related HCC.
Journal
|
KDR (Kinase insert domain receptor) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
KDR expression • HIF1A expression
9ms
VE-cadherin junction dynamics in initial lymphatic vessels promotes lymph node metastasis. (PubMed, Life Sci Alliance)
We conclude that VEGFA mediates zippering of VE-cadherin junctions in initial lymphatics. Zippering is accompanied by increased VE-cadherin fragmentation through VEGFA-induced Src kinase activation, correlating with tumor dissemination to sentinel lymph nodes.
Journal
|
CDH5 (Cadherin 5)
|
EGFR mutation • VEGFA elevation • KDR expression • KDR mutation
9ms
Journal
|
KDR (Kinase insert domain receptor) • NOS3 (Nitric oxide synthase 3)
|
KDR expression • VEGFA expression
|
Caprelsa (vandetanib)
10ms
VEGFR2 Expression Correlates with Postnatal Development of Brain Arteriovenous Malformations in a Mouse Model of Type I Hereditary Hemorrhagic Telangiectasia. (PubMed, Biomedicines)
We employed SclCreER(+);Eng mice, enabling timed Eng gene deletion in endothelial cells via tamoxifen...VEGFR2 expression peaked in the initial 2 postnatal weeks, coinciding with BAVM onset. These findings support the "second hit" theory, highlighting the role of early postnatal angiogenesis in initiating BAVM development in HHT type I mice.
Preclinical • Journal
|
KDR (Kinase insert domain receptor) • VEGFA (Vascular endothelial growth factor A) • ENG (Endoglin)
|
KDR expression
|
tamoxifen
10ms
Transcription Factor FOSL1 Promotes Angiogenesis of Colon Carcinoma by Regulating the VEGF Pathway Through Activating TIMP1. (PubMed, Biochem Genet)
FOSL1 activated VEGF pathway by up-regulating TIMP1 expression, thereby advancing CC angiogenesis. We provided theoretical basis that the FOSL1/TIMP1/VEGF pathway might be a novel option for anti-angiogenesis therapy of CC.
Journal
|
KDR (Kinase insert domain receptor) • FLT4 (Fms-related tyrosine kinase 4) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • FOSL1 (FOS Like 1)
|
KDR expression • FOSL1 expression • VEGFA expression • KIM1 expression • TIMP1 expression
10ms
In vivo antiangiogenic effect of nimbolide, trans-chalcone and piperine for use against glioblastoma. (PubMed, BMC Cancer)
Taken together, NBL, TC and PPR can suppress U87-induced neoangiogenesis via a reduction in VEGF-A and its receptor VEGFR-2 transcript expression at noncytotoxic concentrations. These phytochemicals showed their utility as adjuvants to GBM therapy, with Piperine demonstrating superior effectiveness among them all.
Preclinical • Journal
|
KDR (Kinase insert domain receptor)
|
VEGFA elevation • KDR expression
10ms
Low-dose Cisplatin Induces Tumor Growth via Mobilization of Proangiogenic Bone Marrow-derived Cells in Mouse Models. (PubMed, Anticancer Res)
These results indicate that metronomic CDDP promoted tumor angiogenesis and tumor growth via increased mobilization of proangiogenic BMDCs at certain low doses. This implies a potential therapeutic risk from an inappropriate LDM chemotherapy dosage and suggests that optimizing the LDM chemotherapy regimen is urgently needed.
Preclinical • Journal
|
KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1) • MMP9 (Matrix metallopeptidase 9) • CDH5 (Cadherin 5)
|
KDR expression • CDH1 expression • FLT1 expression
|
cisplatin
10ms
BR55 Ultrasound Molecular Imaging of Clear Cell Renal Cell Carcinoma Reflects Tumor Vascular Expression of VEGFR-2 in a Patient-Derived Xenograft Model. (PubMed, Int J Mol Sci)
Mice were divided into four groups to receive either vehicle or axitinib an amount of 2, 7.5 or 15 mg/kg twice daily...Significant Pearson correlation coefficients were observed between the area under the curve (AUC) and the CD34 (0.84, p < 10), and between the VEGFR-2-specific signal obtained by USMI and IHC (0.72, p < 10). USMI with BR55 could provide instant, quantitative information on tumor VEGFR-2 expression to characterize renal masses non-invasively.
Preclinical • Journal
|
KDR (Kinase insert domain receptor) • CD34 (CD34 molecule)
|
KDR expression
|
Inlyta (axitinib)
10ms
Gastric tubular adenocarcinoma with diffuse neutrophils infiltrating: characteristics and probable treatment strategy. (PubMed, Gastric Cancer)
TADNI is a special morphological subtype with poorer prognoses and unique molecular characteristics, which might benefit from CXCR1/CXCR2 inhibitors.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • KDR (Kinase insert domain receptor) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • MIR223 (MicroRNA 223)
|
PD-L1 expression • HER-2 expression • CD8 expression • CD8 positive • KDR expression
11ms
High Level of Adropin Promotes the Progression of Pancreatic Ductal Adenocarcinoma. (PubMed, Curr Cancer Drug Targets)
Adropin overexpression in PDA promotes cancer cell proliferation and angiogenesis in tumor microenvironment by continuously activating VEGFR2 signaling, thereby creating conditions for tumor progression. Thus, targeting adropin may be an effective anti-PDA strategy.
Journal
|
CCND1 (Cyclin D1) • MMP2 (Matrix metallopeptidase 2)
|
CCND1 expression • KDR expression
11ms
Dihydroartemisinin inhibits melanoma migration and metastasis by affecting angiogenesis. (PubMed, Phytother Res)
DHA inhibits melanoma invasion and metastasis by mediating angiogenesis. These results have important implications for the potential use of DHA in treatment of melanoma.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
KDR expression • CD31 expression
11ms
Low EGFL7 expression is associated with high lymph node spread and invasion of lymphatic vessels in colorectal cancer. (PubMed, Sci Rep)
Finally, we found in silico that EGFL7 expression was associated with cell growth, angiogenesis, and important pathways such as VEGF, Rap-1, MAPK and PI3K/Akt. Expression of EGFL7 in tumor cells may be associated with important pathways that can alter functions related to tumor invasive processes, preventing recurrence and metastatic process.
Journal
|
KDR (Kinase insert domain receptor) • PI3K (Phosphoinositide 3-kinases)
|
KDR expression
11ms
Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study. (PubMed, BMC Cancer)
It was validated that GLS1 was a sensitive and specific biomarker for pathological diagnosis of HCC and had prognostic value, thus having practical value for clinical application.
Journal
|
KDR (Kinase insert domain receptor) • AFP (Alpha-fetoprotein) • GPC3 (Glypican 3) • GLS1 (Glutaminase)
|
KDR expression • GPC3 expression • AFP expression
11ms
Osmundacetone Inhibits Angiogenesis of Infantile Hemangiomas through Inducing Caspases and Reducing VEGFR2/MMP2. (PubMed, Anticancer Agents Med Chem)
OSC demonstrated promising results in inhibiting HemECs' proliferation, inducing apoptosis, and ameliorating pathological changes in hemangiomas in mice. Moreover, it influenced the expression of crucial caspases and angiogenesis-related proteins. These findings suggest that OSC holds potential as a novel drug for clinical treatment of IH.
Journal • PARP Biomarker
|
KDR (Kinase insert domain receptor) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • FADD (Fas associated via death domain) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • MMP9 (Matrix metallopeptidase 9)
|
KDR expression • BAX expression • CASP3 elevation • MMP9 elevation
11ms
Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. (PubMed, Int J Cancer)
Progression-free survival was not reached yet. Apa+ddTCb regimen achieved an improved efficacy and acceptable adverse events compared with ddTCb regimen, which might be a promising strategy in the neoadjuvant therapy for locally advanced TNBC.
Journal • Metastases
|
EGFR (Epidermal growth factor receptor) • KDR (Kinase insert domain receptor)
|
EGFR expression • KDR expression • VEGFA expression
|
carboplatin • paclitaxel • AiTan (rivoceranib)
11ms
Effect of sunitinib against Echinococcus multilocularis through inhibition of VEGFA-induced angiogenesis. (PubMed, Parasit Vectors)
SU11248 is a potential candidate drug for the treatment of AE, which predominantly inhibits parasite-induced angiogenesis. Host-targeted anti-angiogenesis treatment strategies constitute a new avenue for the treatment of AE.
Journal
|
IL4 (Interleukin 4)
|
KDR expression • VEGFA expression • IL4 elevation
|
sunitinib
11ms
VEGFR2-specific CAR-T cells show improved tumor infiltration in syngeneic mouse glioma models (SNO 2023)
VEGFR2-CAR-T cells show improved glioma infiltration in syngeneic mouse models. Therefore, VEGFR2 might be a relevant target that could improve CAR-T cell infiltration in glioblastoma.
Preclinical • CAR T-Cell Therapy
|
KDR (Kinase insert domain receptor)
|
KDR expression
11ms
TiO nanoparticles promote tumor metastasis by eliciting pro-metastatic extracellular vesicles. (PubMed, J Nanobiotechnology)
Mechanically, miR-301a-3p derived from NPs-elicited EVs could be delivered into vascular endothelial cells, which inhibited the expression of VEGFR2 and VE-cadherin by targeting S1PR1, leading to disrupt the tight junctions of vascular endothelial cells, thus to promote vascular permeability and angiogenesis, and induce the formation of pre-metastasis niches in vivo. This study emphasizes that it is urgent to consider the effect of NPs on EVs under long-term use conditions when designing nanodrugs for cancer treatment.
Journal • Metastases
|
KDR (Kinase insert domain receptor) • CDH5 (Cadherin 5) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)
|
KDR expression • CDH1 expression